CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 53.74 USD -0.59% Market Closed
Updated: Jun 2, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Cash Flow Statement

-159.4m
+39%
Operating Cash Flow
Growth Rates:
1 Year
+55%
3 Years
+44%
5 Years
-36%
7 Years
-132%
10 Years
-
159m
-58%
Investing Cash Flow
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
+1 687%
10 Years
-
363.2m
+480%
Financing Cash Flow
Growth Rates:
1 Year
+987%
3 Years
-71%
5 Years
+68%
7 Years
+145%
10 Years
-

Cash Flow Statement
CRISPR Therapeutics AG

Rotate your device to view
Cash Flow Statement
Currency: USD
Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Operating Cash Flow
Net Income
(26)
(31)
(44)
(53)
(23)
(36)
(41)
(51)
(68)
(75)
(91)
(117)
(165)
(185)
(200)
(11)
67
46
20
(211)
(349)
(392)
447
412
378
312
(634)
(681)
(650)
(524)
(416)
(354)
(154)
(217)
Depreciation & Amortization
0
0
0
1
1
2
2
3
3
3
3
3
4
4
4
4
5
6
7
8
9
10
11
14
18
21
25
25
24
23
21
21
20
20
Stock-Based Compensation
4
5
8
10
11
13
13
16
19
21
26
29
35
39
42
45
44
49
53
59
66
74
87
96
102
106
103
101
98
93
90
85
81
80
Other Non-Cash Items
4
0
4
6
(35)
(29)
(29)
(26)
21
24
29
48
55
59
62
52
34
38
41
44
68
77
92
106
117
124
122
118
110
99
89
76
67
58
Change in Working Capital
81
82
80
80
2
(5)
(3)
(0)
(25)
(21)
(19)
(16)
11
6
7
(20)
(48)
(41)
(13)
6
33
19
(0)
12
27
47
42
70
20
51
(37)
(21)
(194)
(20)
Cash from Operating Activities
59
N/A
51
-14%
40
-21%
33
-17%
(55)
N/A
(69)
-24%
(71)
-3%
(75)
-5%
(70)
+6%
(69)
+1%
(79)
-13%
(83)
-5%
(96)
-16%
(117)
-22%
(128)
-10%
25
N/A
57
+127%
48
-15%
55
+15%
(154)
N/A
(238)
-55%
(287)
-20%
549
N/A
544
-1%
539
-1%
505
-6%
(445)
N/A
(468)
-5%
(496)
-6%
(352)
+29%
(343)
+3%
(278)
+19%
(260)
+6%
(159)
+39%
Investing Cash Flow
Capital Expenditures
(1)
(1)
(2)
(3)
(3)
(6)
(6)
(8)
(8)
(5)
(4)
(2)
(3)
(3)
(5)
(7)
(7)
(9)
(10)
(13)
(18)
(22)
(47)
(79)
(82)
(90)
(71)
(40)
(37)
(25)
(20)
(17)
(12)
(10)
Other Items
0
20
20
20
35
15
0
15
(1)
0
0
0
0
0
0
0
8
0
0
(317)
(523)
(684)
(949)
(1 152)
(954)
(892)
(673)
(52)
(222)
(1)
267
298
387
169
Cash from Investing Activities
(1)
N/A
19
N/A
18
-5%
17
-5%
32
+92%
9
-72%
9
-2%
7
-23%
(8)
N/A
(6)
+33%
(5)
+14%
(2)
+58%
(3)
-40%
(3)
-18%
(5)
-52%
(7)
-34%
1
N/A
(1)
N/A
(2)
-233%
(330)
-16 395%
(541)
-64%
(706)
-30%
(996)
-41%
(1 231)
-24%
(1 035)
+16%
(982)
+5%
(745)
+24%
(92)
+88%
(259)
-182%
(26)
+90%
247
N/A
281
+14%
375
+34%
159
-58%
Financing Cash Flow
Net Issuance of Common Stock
59
54
62
61
115
115
55
55
3
128
131
319
316
216
242
125
431
406
466
908
1 016
1 241
1 160
657
251
36
38
42
39
33
40
26
63
363
Net Issuance of Debt
38
73
73
73
35
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other
(0)
(0)
(0)
(5)
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash from Financing Activities
97
N/A
126
+31%
134
+6%
130
-3%
183
+41%
148
-19%
88
-41%
93
+6%
3
-97%
128
+4 819%
131
+2%
319
+143%
316
-1%
216
-32%
242
+12%
125
-48%
431
+245%
406
-6%
466
+15%
908
+95%
1 016
+12%
1 241
+22%
1 160
-7%
657
-43%
251
-62%
36
-86%
38
+6%
42
+13%
39
-9%
33
-13%
40
+19%
26
-34%
63
+139%
363
+480%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
(0)
(0)
(0)
(0)
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
0
0
0
0
Net Change in Cash
155
N/A
196
+26%
192
-2%
180
-7%
160
-11%
88
-45%
25
-71%
25
-2%
(76)
N/A
53
N/A
48
-10%
234
+392%
217
-7%
96
-56%
109
+14%
143
+32%
489
+241%
454
-7%
520
+14%
425
-18%
237
-44%
248
+5%
713
+188%
(30)
N/A
(246)
-721%
(442)
-80%
(1 152)
-161%
(518)
+55%
(716)
-38%
(345)
+52%
(56)
+84%
29
N/A
177
+506%
363
+105%
Free Cash Flow
Free Cash Flow
58
N/A
50
-15%
38
-24%
30
-21%
(58)
N/A
(75)
-28%
(77)
-3%
(83)
-7%
(78)
+6%
(75)
+4%
(83)
-11%
(85)
-2%
(99)
-17%
(121)
-22%
(133)
-11%
18
N/A
50
+173%
40
-21%
45
+14%
(167)
N/A
(257)
-54%
(309)
-20%
502
N/A
465
-7%
457
-2%
414
-9%
(516)
N/A
(509)
+1%
(533)
-5%
(377)
+29%
(363)
+4%
(295)
+19%
(272)
+8%
(169)
+38%

See Also

Summary
CRSP intrinsic value, competitors valuation, and company profile.
DCF Valuation
CRSP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CRSP stock valuation using valuation multiples.
Wall Street Estimates
CRSP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CRSP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 142,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.